Elicit: Immunomodulatory Effects of IVIG in Humoral Immunodeficiency

Immunomodulatory Effects of IVIG in Humoral Immunodeficiency

What are the immunomodulatory mechanisms of intravenous immunoglobulin in primary humoral immunodeficiency?

Intravenous immunoglobulin (IVIG) exerts immunomodulatory effects through biphasic cytokine modulation, partial T cell reconstitution, dual B cell activation and selective depletion via anergy induction, and normalization of antigen-presenting cell function, with these mechanisms operating through distinct temporal phases and varying by patient subtype and cellular context.

Abstract

IVIG therapy in primary humoral immunodeficiency produces biphasic cytokine modulation. Initial elevation of IL-2, IL-10, IL-6, IL-8, and TNF-α is observed post-infusion, followed by sustained down-regulation of the IL-1 system and restoration of CD4+ counts. B cell effects induce proliferation and immunoglobulin synthesis but also drive B cells toward an anergic state.

Methods

We analyzed 10 sources with defined screening criteria focusing on primary humoral immunodeficiency, IVIG intervention, and immunomodulatory mechanisms in human studies.

Characteristics of Included Studies

All 10 included sources investigated mechanisms of IVIG in primary humoral immunodeficiencies, mostly focusing on common variable immunodeficiency (CVID).

Study Full text retrieved? Diagnosis Diagnostic criteria Sample size Study type
K. Kasztalska et al., 2011 No CVID ESID clinical criteria; low IgG, IgA, or IgM 17 CVID patients, 7 healthy controls Prospective trial
J. Bayry et al., 2011 No CVID Not mentioned Not mentioned Mechanistic study
Dominic Paquin-Proulx et al., 2013 Yes CVID Pan-American Group criteria 12 CVID patients, 13 healthy controls Prospective cohort
P. Aukrust et al., 1997 No Primary hypogammaglobulinemia Not mentioned 12 patients Intervention study

IVIG Treatment Protocols

IVIG administration protocols varied across studies.

Study IVIG preparation Dose Route Treatment history Follow-up duration
K. Kasztalska et al., 2011 Flebogamma 5% 300 mg/kg IV infusion Not specified 2 weeks
Dominic Paquin-Proulx et al., 2013 Not mentioned Not mentioned IV Newly started 6-12 months

Immunomodulatory Mechanisms

Cytokine Modulation

IVIG therapy demonstrated complex effects on cytokine networks.

Study Cytokines measured Direction of change Magnitude Measurement timing
K. Kasztalska et al., 2011 IL-2, IL-10 Increase IL-2: p=0.0004; IL-10: p=0.0003 30 min post-infusion
C. Ibáñez et al., 2012 IL-6, IL-8, IL-1Ra, TNF-α All increased Significant increases 1 hour post-infusion

T Cell Effects

IVIG therapy induced multiple changes in T cell populations.

Study T cell parameter Direction Magnitude Timing
K. Kasztalska et al., 2011 CD4+ T cells Increase p=0.028 30 min post-infusion
Dominic Paquin-Proulx et al., 2013 CD8+ T cell activation Decrease Significant reductions in Ki67, CD38 6-12 months

B Cell Effects

IVIG exerted profound effects on B cell function.

Study B cell mechanism Effect observed Clinical significance
J. Bayry et al., 2011 Proliferation and Ig synthesis Induced at low doses Rectifies defective B cell signaling
Z. Krátká et al., 2002 IgA and IgM production Suppressed in IgG subclass deficiency Immunosuppressive effect

Antigen-Presenting Cell Effects

IVIG modulated the function of antigen-presenting cells.

Study Cell type Parameter Effect
Dominic Paquin-Proulx et al., 2013 Myeloid dendritic cells Cell numbers Partial restoration
P. Aukrust et al., 1997 Monocytes/macrophages Zymosan-stimulated ROS Decreased

Synthesis

The immunomodulatory mechanisms of IVIG in primary humoral immunodeficiency reveal complexity with temporal dynamics, context-specific activation, and an interplay of immune pathways.

References